{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:39:09Z","timestamp":1791895149953,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-024-01024-6","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T07:46:21Z","timestamp":1732520781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ad26.RSV.preF completely protects calves from severe respiratory disease induced by bovine RSV challenge"],"prefix":"10.1038","volume":"9","author":[{"given":"Leslie","family":"van der Fits","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2052-5993","authenticated-orcid":false,"given":"Rineke","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5395-505X","authenticated-orcid":false,"given":"Karin","family":"Dijkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Heemskerk-van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisanne","family":"Tettero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Bonsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Serroyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianke","family":"van Schie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Stockhofe-Zurwieden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Callendret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2822-6231","authenticated-orcid":false,"given":"Roland","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"1024_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","volume":"388","author":"A Papi","year":"2023","unstructured":"Papi, A. et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N. Engl. J. Med. 388, 595\u2013608 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1024_CR2","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","volume":"388","author":"EE Walsh","year":"2023","unstructured":"Walsh, E. E. et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N. Engl. J. Med. 388, 1465\u20131477 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1024_CR3","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","volume":"389","author":"E Wilson","year":"2023","unstructured":"Wilson, E. et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N. Engl. J. Med. 389, 2233\u20132244 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1024_CR4","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","volume":"399","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 399, 2047\u20132064 (2022).","journal-title":"Lancet"},{"key":"1024_CR5","doi-asserted-by":"publisher","unstructured":"Rocca, A. et al. Passive immunoprophylaxis against respiratory syncytial virus in children: where are we now? Int. J. Mol. Sci. 22, https:\/\/doi.org\/10.3390\/ijms22073703 (2021).","DOI":"10.3390\/ijms22073703"},{"key":"1024_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40265-022-01829-6","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam, S. J. Nirsevimab: first approval. Drugs 83, 181\u2013187 (2023).","journal-title":"Drugs"},{"key":"1024_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40272-023-00598-3","volume":"25","author":"YY Syed","year":"2023","unstructured":"Syed, Y. Y. Respiratory syncytial virus prefusion F subunit vaccine: first approval of a maternal vaccine to protect infants. Paediatr. Drugs 25, 729\u2013734 (2023).","journal-title":"Paediatr. Drugs"},{"key":"1024_CR8","doi-asserted-by":"publisher","unstructured":"Biagi, C. et al. Current state and challenges in developing respiratory syncytial virus vaccines. Vaccines (Basel) 8, https:\/\/doi.org\/10.3390\/vaccines8040672 (2020).","DOI":"10.3390\/vaccines8040672"},{"key":"1024_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","volume":"89","author":"HW Kim","year":"1969","unstructured":"Kim, H. W. et al. Respiratory Syncitial Virus Disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422\u2013434 (1969).","journal-title":"Am. J. Epidemiol."},{"key":"1024_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/oxfordjournals.aje.a120954","volume":"89","author":"AZ Kapikian","year":"1969","unstructured":"Kapikian, A. Z., Mitchell, R. H., Chanock, R. M., Shvedoff, R. A. & Stewart, C. E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89, 405\u2013421 (1969).","journal-title":"Am. J. Epidemiol."},{"key":"1024_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/oxfordjournals.aje.a120956","volume":"89","author":"VA Fulginiti","year":"1969","unstructured":"Fulginiti, V. A. et al. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89, 435\u2013448 (1969).","journal-title":"Am. J. Epidemiol."},{"key":"1024_CR12","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1186\/rr184","volume":"3","author":"PJ Openshaw","year":"2002","unstructured":"Openshaw, P. J. Potential therapeutic implications of new insights into respiratory syncytial virus disease. Respir. Res. 3, S15\u2013S20 (2002).","journal-title":"Respir. Res."},{"key":"1024_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/1348-0421.12365","volume":"60","author":"A Sawada","year":"2016","unstructured":"Sawada, A. & Nakayama, T. Experimental animal model for analyzing immunobiological responses following vaccination with formalin-inactivated respiratory syncytial virus. Microbiol Immunol. 60, 234\u2013242 (2016).","journal-title":"Microbiol Immunol."},{"key":"1024_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1128\/CVI.00609-15","volume":"23","author":"PL Acosta","year":"2015","unstructured":"Acosta, P. L., Caballero, M. T. & Polack, F. P. Brief history and characterization of enhanced respiratory syncytial virus disease. Clin. Vaccin. Immunol. 23, 189\u2013195 (2015).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1024_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/14760584.2017.1260452","volume":"16","author":"A Muralidharan","year":"2017","unstructured":"Muralidharan, A., Li, C., Wang, L. & Li, X. Immunopathogenesis associated with formaldehyde-inactivated RSV vaccine in preclinical and clinical studies. Expert Rev. Vaccines 16, 351\u2013360 (2017).","journal-title":"Expert Rev. Vaccines"},{"key":"1024_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1177\/0300985813501341","volume":"51","author":"RE Sacco","year":"2014","unstructured":"Sacco, R. E., McGill, J. L., Pillatzki, A. E., Palmer, M. V. & Ackermann, M. R. Respiratory syncytial virus infection in cattle. Vet. Pathol. 51, 427\u2013436 (2014).","journal-title":"Vet. Pathol."},{"key":"1024_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1051\/vetres:2006053","volume":"38","author":"JF Valarcher","year":"2007","unstructured":"Valarcher, J. F. & Taylor, G. Bovine respiratory syncytial virus infection. Vet. Res. 38, 153\u2013180 (2007).","journal-title":"Vet. Res."},{"key":"1024_CR18","doi-asserted-by":"publisher","first-page":"12067","DOI":"10.1128\/JVI.77.22.12067-12073.2003","volume":"77","author":"AF Antonis","year":"2003","unstructured":"Antonis, A. F. et al. Vaccine-induced immunopathology during bovine respiratory syncytial virus infection: exploring the parameters of pathogenesis. J. Virol. 77, 12067\u201312073 (2003).","journal-title":"J. Virol."},{"key":"1024_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.vaccine.2016.11.054","volume":"35","author":"G Taylor","year":"2017","unstructured":"Taylor, G. Animal models of respiratory syncytial virus infection. Vaccine 35, 469\u2013480 (2017).","journal-title":"Vaccine"},{"key":"1024_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.molimm.2014.12.004","volume":"66","author":"E Guzman","year":"2015","unstructured":"Guzman, E. & Taylor, G. Immunology of bovine respiratory syncytial virus in calves. Mol. Immunol. 66, 48\u201356 (2015).","journal-title":"Mol. Immunol."},{"key":"1024_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2023.101337","volume":"61","author":"RJ Miller","year":"2023","unstructured":"Miller, R. J. & Mousa, J. J. Structural basis for respiratory syncytial virus and human metapneumovirus neutralization. Curr. Opin. Virol. 61, 101337 (2023).","journal-title":"Curr. Opin. Virol."},{"key":"1024_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33649-3","volume":"13","author":"R de Jong","year":"2022","unstructured":"de Jong, R. et al. ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infection-induced disease in young calves. Nat. Commun. 13, 6142 (2022).","journal-title":"Nat. Commun."},{"key":"1024_CR23","doi-asserted-by":"publisher","unstructured":"Guerra-Maupome, M., Palmer, M. V., McGill, J. L. & Sacco, R. E. Utility of the neonatal calf model for testing vaccines and intervention strategies for use against human RSV infection. Vaccines (Basel) 7, https:\/\/doi.org\/10.3390\/vaccines7010007 (2019).","DOI":"10.3390\/vaccines7010007"},{"key":"1024_CR24","doi-asserted-by":"publisher","unstructured":"Bourassa, M. H. & Lands, L. C. Preventative therapies for respiratory Syncytial virus (RSV) in children: where are we now? Paediatr. Respir. Rev., https:\/\/doi.org\/10.1016\/j.prrv.2023.08.005 (2023).","DOI":"10.1016\/j.prrv.2023.08.005"},{"key":"1024_CR25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.immuni.2019.08.007","volume":"51","author":"TJ Ruckwardt","year":"2019","unstructured":"Ruckwardt, T. J., Morabito, K. M. & Graham, B. S. Immunological lessons from respiratory syncytial virus vaccine development. Immunity 51, 429\u2013442 (2019).","journal-title":"Immunity"},{"key":"1024_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00734-7","volume":"8","author":"TJ Ruckwardt","year":"2023","unstructured":"Ruckwardt, T. J. The road to approved vaccines for respiratory syncytial virus. NPJ Vaccines 8, 138 (2023).","journal-title":"NPJ Vaccines"},{"key":"1024_CR27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/infdis\/jiaa193","volume":"222","author":"K Williams","year":"2020","unstructured":"Williams, K. et al. Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion F (Ad26.RSV.preF) in adults aged \u226560 years. J. Infect. Dis. 222, 979\u2013988 (2020).","journal-title":"J. Infect. Dis."},{"key":"1024_CR28","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/infdis\/jiab003","volume":"226","author":"J Sadoff","year":"2022","unstructured":"Sadoff, J. et al. Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of Ad26.RSV.preF in a human challenge study. J. Infect. Dis. 226, 396\u2013406 (2022).","journal-title":"J. Infect. Dis."},{"key":"1024_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0200-y","volume":"5","author":"L van der Fits","year":"2020","unstructured":"van der Fits, L. et al. Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice. npj Vaccines 5, 49 (2020).","journal-title":"npj Vaccines"},{"key":"1024_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/infdis\/jiac407","volume":"227","author":"ASV Stuart","year":"2022","unstructured":"Stuart, A. S. V. et al. Phase 1\/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18\u201350 Years and RSV-Seropositive Children 12\u201324 Months. J. Infect. Dis. 227, 71\u201382 (2022).","journal-title":"J. Infect. Dis."},{"key":"1024_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.vaccine.2019.10.048","volume":"38","author":"SK Browne","year":"2020","unstructured":"Browne, S. K., Beeler, J. A. & Roberts, J. N. Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naive infants. Vaccine 38, 101\u2013106 (2020).","journal-title":"Vaccine"},{"key":"1024_CR32","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S0264-410X(98)80123-0","volume":"16","author":"LJ Gershwin","year":"1998","unstructured":"Gershwin, L. J. et al. A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology. Vaccine 16, 1225\u20131236 (1998).","journal-title":"Vaccine"},{"key":"1024_CR33","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0264-410X(98)00379-X","volume":"17","author":"AR Woolums","year":"1999","unstructured":"Woolums, A. R., Singer, R. S., Boyle, G. A. & Gershwin, L. J. Interferon gamma production during bovine respiratory syncytial virus (BRSV) infection is diminished in calves vaccinated with formalin-inactivated BRSV. Vaccine 17, 1293\u20131297 (1999).","journal-title":"Vaccine"},{"key":"1024_CR34","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1016\/j.vaccine.2005.04.032","volume":"23","author":"WV Kalina","year":"2005","unstructured":"Kalina, W. V., Woolums, A. R. & Gershwin, L. J. Formalin-inactivated bovine RSV vaccine influences antibody levels in bronchoalveolar lavage fluid and disease outcome in experimentally infected calves. Vaccine 23, 4625\u20134630 (2005).","journal-title":"Vaccine"},{"key":"1024_CR35","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0264-410X(98)00265-5","volume":"17","author":"K West","year":"1999","unstructured":"West, K. et al. The effect of formalin-inactivated vaccine on respiratory disease associated with bovine respiratory syncytial virus infection in calves. Vaccine 17, 809\u2013820 (1999).","journal-title":"Vaccine"},{"key":"1024_CR36","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1046\/j.1439-0450.2000.00380.x","volume":"47","author":"P Schreiber","year":"2000","unstructured":"Schreiber, P. et al. High mortality rate associated with bovine respiratory syncytial virus (BRSV) infection in Belgian white blue calves previously vaccinated with an inactivated BRSV vaccine. J. Vet. Med B Infect. Dis. Vet. Public Health 47, 535\u2013550 (2000).","journal-title":"J. Vet. Med B Infect. Dis. Vet. Public Health"},{"key":"1024_CR37","doi-asserted-by":"publisher","unstructured":"Cox, F. et al. RSV A2-based prefusion F vaccine candidates induce RSV A and RSV B cross binding and neutralizing antibodies and provide protection against RSV A and RSV B challenge in preclinical models. Vaccines (Basel) 11, https:\/\/doi.org\/10.3390\/vaccines11030672 (2023).","DOI":"10.3390\/vaccines11030672"},{"key":"1024_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg6050","volume":"15","author":"L Sacconnay","year":"2023","unstructured":"Sacconnay, L. et al. The RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically distant respiratory syncytial virus strains. Sci. Transl. Med. 15, eadg6050 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1024_CR39","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","volume":"388","author":"B Kampmann","year":"2023","unstructured":"Kampmann, B. et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N. Engl. J. Med. 388, 1451\u20131464 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1024_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1206026","volume":"14","author":"JL Kosanovich","year":"2023","unstructured":"Kosanovich, J. L. et al. Exacerbated lung inflammation following secondary RSV exposure is CD4+ T cell-dependent and is not mitigated in infant BALB\/c mice born to PreF-vaccinated dams. Front Immunol. 14, 1206026 (2023).","journal-title":"Front Immunol."},{"key":"1024_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.vetmic.2016.11.030","volume":"206","author":"JA Ellis","year":"2017","unstructured":"Ellis, J. A. How efficacious are vaccines against bovine respiratory syncytial virus in cattle? Vet. Microbiol. 206, 59\u201368 (2017).","journal-title":"Vet. Microbiol."},{"key":"1024_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2022.906636","volume":"9","author":"DA Martinez","year":"2022","unstructured":"Martinez, D. A., Newcomer, B., Passler, T. & Chamorro, M. F. Efficacy of Bovine Respiratory Syncytial Virus Vaccines to Reduce Morbidity and Mortality in Calves Within Experimental Infection Models: A Systematic Review and Meta-Analysis. Front Vet. Sci. 9, 906636 (2022).","journal-title":"Front Vet. Sci."},{"key":"1024_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0005-9","volume":"2","author":"B Zhang","year":"2017","unstructured":"Zhang, B. et al. Protection of calves by a prefusion-stabilized bovine RSV F vaccine. NPJ Vaccines 2, 7 (2017).","journal-title":"NPJ Vaccines"},{"key":"1024_CR44","doi-asserted-by":"publisher","unstructured":"Riffault, S. et al. A Single Shot Pre-fusion-Stabilized Bovine RSV F Vaccine is Safe and Effective in Newborn Calves with Maternally Derived Antibodies. Vaccines (Basel) 8, https:\/\/doi.org\/10.3390\/vaccines8020231 (2020).","DOI":"10.3390\/vaccines8020231"},{"key":"1024_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9143","volume":"6","author":"A Krarup","year":"2015","unstructured":"Krarup, A. et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun. 6, 8143 (2015).","journal-title":"Nat. Commun."},{"key":"1024_CR46","doi-asserted-by":"publisher","first-page":"300ra127","DOI":"10.1126\/scitranslmed.aac5757","volume":"7","author":"G Taylor","year":"2015","unstructured":"Taylor, G. et al. Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections. Sci. Transl. Med 7, 300ra127 (2015).","journal-title":"Sci. Transl. Med"},{"key":"1024_CR47","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s007050050288","volume":"143","author":"JP Langedijk","year":"1998","unstructured":"Langedijk, J. P., Meloen, R. H. & van Oirschot, J. T. Identification of a conserved neutralization site in the first heptad repeat of the fusion protein of respiratory syncytial virus. Arch. Virol. 143, 313\u2013320 (1998).","journal-title":"Arch. Virol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01024-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01024-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01024-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T09:02:21Z","timestamp":1732525341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01024-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1024"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-01024-6","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors K.D., M.H.-v.d.M., L.T., J.S., M.v.S., B.C., R.Z., and L.v.d.F. are (former) employees of Janssen Infectious Diseases & Vaccines and may own stock or stock options in Johnson & Johnson, its parent company, but declare no non-financial competing interests. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"235"}}